Serum choline plasmalogens, particularly those with oleic acid in sn -2, are associated with proatherogenic state

Journal of Lipid Research

Volumn 55, Issue 5, 2014, Pages 956-965

  Nishimukai, Megumi ^a,b   Maeba, Ryouta ^c   Yamazaki, Yuya ^d   Nezu, Toru ^d   Sakurai, Toshihiro ^a   Takahashi, Yuji ^a   Hui, Shu Ping ^a   Chiba, Hitoshi ^a   Okazaki, Tomoki ^c   Hara, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b IWATE UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d ADEKA CORPORATION   (Japan)

Author keywords

Atherosclerosis; Ether glycerophospholipid; High density lipoprotein cholesterol; Serum biomarker

Indexed keywords

ADIPONECTIN; ETHER GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLEIC ACID; PLASMALOGEN; PLASMALOGEN CHOLINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLINE PLASMALOGENS;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; JAPANESE (PEOPLE); LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CHEMISTRY; COHORT ANALYSIS; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OLEIC ACID; PLASMALOGENS; RISK FACTORS; YOUNG ADULT;

EID: 84899503183     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P045591     Document Type: Article

References (45)

1. Braverman, N. E., and A. B. Moser. 2012. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta. 1822 : 1442-1452.
2. Brites, P., H. R. Waterham, and R. J. A. Wanders. 2004. Functions and biosynthesis of plasmalogen in health and disease. Biochim. Biophys. Acta. 1636 : 219-231.
3. Wanders, R. J. A., and H. R. Waterham. 2006. Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochim. Biophys. Acta. 1763 : 1707-1720.
4. Han, X., D. M. Holtzman, and D. W. Jr. McKeel. 2001. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77 : 1168-1180.
5. Goodenowe, D. B., L. L. Cook, J. Liu, Y. Lu, D. A. Jayasinghe, P. W. Ahiahonu, D. Heath, Y. Yamazaki, J. Flax, K. F. Krenitsky, et al. 2007. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48 : 2485-2498.
6. Wallner, S., and G. Schmitz. 2011. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids. 164 : 573-589.
7. Oresic, M., S. Simell, M. Sysi-Aho, K. Näntö-Salonen, T. Seppänen-Laakso, V. Parikka, M. Katajamaa, A. Hekkala, I. Mattila, P. Keskinen, et al. 2008. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J. Exp. Med. 205 : 2975-2984.
8. Colas, R., A. Sassolas, M. Guichardant, C. Cugnet-Anceau, M. Moret, P. Moulin, M. Lagarde, and C. Calzada. 2011. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia. 54 : 2931-2940.
9. Stenvinkel, P., U. Diczfalusy, B. Lindholm, and O. Heimbürger. 2004. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol. Dial. Transplant. 19 : 972-976.
10. Graessler, J., D. Schwudke, P. E. Schwarz, R. Herzog, A. Shevchenko, and S. R. Bornstein. 2009. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS ONE. 4 : e6261.
11. Farooqui, A. A., W. Y. Ong, and L. A. Horrocks. 2006. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 58 : 591-620.
12. Lessig, J., and B. Fuchs. 2009. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr. Med. Chem. 16 : 2021-2041.
13. Zoeller, R. A., A. C. Lake, N. Nagan, D. P. Gaposchkin, M. A. Legner, and W. Lieberthal. 1999. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of vinyl ether. Biochem. J. 338 : 769-776.
14. Hahnel, D., J. Thiery, T. Brosche, and B. Engelmann. 1999. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arterioscler. Thromb. Vasc. Biol. 19 : 2431-2438.
15. Maeba, R., and N. Ueta. 2003. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 44 : 164-171.
16. Nishimukai, M., M. Yamashita, Y. Watanabe, Y. Yamazaki, T. Nezu, R. Maeba, and H. Hara. 2011. Lymphatic absorption of choline plasmalogen is much higher than that of ethanolamine plasmalogen in rats. Eur. J. Nutr. 50 : 427-436.
17. Hui, S. P., H. Chiba, and T. Kurosawa. 2011. Liquid chromatography-mass spectrometric determination of plasmalogens in human plasma. Anal. Bioanal. Chem. 400 : 1923-1931.
18. Zemski Berry, K. A., and R. C. Murphy. 2004. Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids. J. Am. Soc. Mass Spectrom. 15 : 1499-1508.
19. Norris, C., B. Fong, A. MacGibbon, and P. McJarrow. 2009. Analysis of phospholipids in rat brain using liquid chromatography-mass spectrometry. Lipids. 44 : 1047-1054.
20. Lee, T. C. 1998. Biosynthesis and possible biological functions of plasmalogens. Biochim. Biophys. Acta. 1394 : 129-145.
21. Watschinger, K., and E. R. Werner. 2013. Orphan enzymes in ether lipid metabolism. Biochimie. 95 : 59-65.
22. Maeba, R., T. Maeda, M. Kinoshita, K. Takao, H. Takenaka, J. Kusano, N. Yoshimura, Y. Takeoka, D. Yasuda, T. Okazaki, et al. 2007. Plasmalogens in human serum positively correlate with highdensity lipoprotein and decrease with aging. J. Atheroscler. Thromb. 14 : 12-18.
23. Skaff, O., D. I. Pattison, and M. J. Davies. 2008. The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidasederived oxidants: a kinetic study. Biochemistry. 47 : 8237-8245.
24. Vance, J. E. 1990. Lipoproteins secreted by cultured rat hepatocytes contain the antioxidant 1-alk-1-enyl-2-acylglycerophosphoethanolamine. Biochim. Biophys. Acta. 1045 : 128-134.
25. Vance, D. E. 2013. Physiological roles of phosphatidylethanolamine N-methyltransferase. Biochim. Biophys. Acta. 1831 : 626-632.
26. Morita, S. Y., A. Takeuchi, and S. Kitagawa. 2010. Functional analysis of two isoforms of phosphatidylethanolamine N-methyltransferase. Biochem. J. 432 : 387-398.
27. Song, J., K. A. da Costa, L. M. Fischer, M. Kohlmeier, L. Kwock, S. Wang, and S. H. Zeisel. 2005. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19 : 1266-1271.
28. Dong, H., J. Wang, C. Li, A. Hirose, Y. Nozaki, M. Takahashi, M. Ono, N. Akisawa, S. Iwasaki, T. Saibara, et al. 2007. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46 : 915-920.
29. Pacifico, L., V. Nobili, C. Anania, P. Verdecchia, and C. Chiesa. 2011. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J. Gastroenterol. 17 : 3082-3091.
30. Puri, P., M. M. Wiest, O. Cheung, F. Mirshahi, C. Sargeant, H. K. Min, M. J. Contos, R. K. Sterling, M. Fuchs, H. Zhou, et al. 2009. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50 : 1827-1838.
31. Maeba, R., H. Hara, H. Ishikawa, S. Hayashi, N. Yoshimura, J. Kusano, Y. Takeoka, D. Yasuda, T. Okazaki, M. Kinoshita, et al. 2008. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J. Nutr. Sci. Vitaminol. (Tokyo). 54 : 196-202.
32. Meyer, M. C., and J. McHowat. 2007. Calcium-independent phospholipase A2-catalyzed plasmalogen hydrolysis in hypoxic human coronary artery endothelial cells. Am. J. Physiol. Cell Physiol. 292 : C251-C258.
33. Chakravarthy, M. V., I. J. Lodhi, L. Yin, R. R. Malapaka, H. E. Xu, J. Turk, and C. F. Semenkovich. 2009. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 138 : 476-488.
34. Fruchart, J. C. 2001. Peroxisome proliferator-activated receptoralpha activation and high-density lipoprotein metabolism. Am. J. Cardiol. 88 : 24N-29N.
35. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7 : 53-58.
36. Leisewitz, A. V., C. R. Urrutia, G. R. Martinez, G. Loyola, and M. Bronfman. 2008. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. J. Cell. Physiol. 217 : 367-376.
37. Wiesner, P., K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch. 2009. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 50 : 574-585.
38. Laurila, P. P., I. Surakka, A. P. Sarin, L. Yetukuri, T. Hyötyläinen, S. Söderlund, J. Naukkarinen, J. Tang, J. Kettunen, D. B. Mirel, et al. 2013. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol. 33 : 847-857.
39. Yancey, P. G., M. Llera-Moya, and S. Swarnakar. 2000. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275 : 36596-36604.
40. Yancey, P. G., M. A. Kawashiri, R. Moore, J. M. Glick, D. L. Williams, M. A. Connelly, D. J. Rader, and G. H. Rothblat. 2004. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J. Lipid Res. 45 : 337-346.
41. Kontush, A., M. Lhomme, and M. J. Chapman. 2013. High density lipoprotein structure, function, and metabolism: unraveling the complexities of the HDL lipidome. J. Lipid Res. 54 : 2950-2963.
42. Gauster, M., O. V. Oskolkova, J. Innerlohinger, O. Glatter, G. Knipping, and S. Frank. 2004. Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux. Biochem. J. 382 : 75-82.
43. Mandel, H., R. Sharf, M. Berant, R. J. Wanders, P. Vreken, and M. Aviram. 1998. Plasmalogen phospholipids are involved in HDLmediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. Biochem. Biophys. Res. Commun. 250 : 369-373.
44. Munn, N. J., E. Arnio, D. Liu, R. A. Zoeller, and L. Liscum. 2003. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J. Lipid Res. 44 : 182-192.
45. Mankidy, R., P. W. Ahiahonu, H. Ma, D. Jayasinghe, S. A. Ritchie, M. A. Khan, K. K. Su-Myat, P. L. Wood, and D. B. Goodenowe. 2010. Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis. 9 : 62.